TradingKey

Mais detalhes de Edwards Lifesciences Corp Empresa

Edwards Lifesciences Corporation is the global structural heart company. The Company partners with clinicians and researchers and invests in research and development to improve care for those impacted by structural heart disease. Its product categories include Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), and Surgical Structural Heart. It provides transcatheter heart valve replacement technologies designed for the minimally-invasive replacement of aortic heart valves. TAVR category includes the Edwards SAPIEN 3, the Edwards SAPIEN 3 Ultra and the Edwards SAPIEN 3 Ultra RESILIA systems. TMTT category includes the PASCAL Precision transcatheter repair system, EVOQUE tricuspid valve replacement system and Cardioband tricuspid valve reconstruction system. Its INSPIRIS RESILIA aortic valve, offers RESILIA tissue and VFit technology. It is managed in various geographical regions, such as United States, Europe, Japan and Rest of World.

Informações da empresa

Código da empresaEW

Nome da EmpresaEdwards Lifesciences Corp

Data de listagemMar 27, 2000

Fundado em1999

CEOMr. Bernard J. Zovighian

Número de funcionários15800

Tipo de títulosOrdinary Share

Fim do ano fiscalMar 27

EndereçoOne Edwards Way

CidadeIRVINE

Bolsa de valoresNYSE Consolidated

PaísUnited States of America

Código postal92614

Telefone19492502500

Sitehttps://www.edwards.com

Código da empresaEW

Data de listagemMar 27, 2000

Fundado em1999

Executivos da empresa

Nome

Nome/Posição

Posição

Ações detidas

Variação

Mr. Scott B. Ullem

Chief Financial Officer, Corporate Vice President

282.82K

+3.48%

Mr. Larry L. Wood

Corporate Vice President, Group President - Transcatheter Aortic Valve Replacement (TAVR) and Surgical Structural Heart

186.44K

--

Mr. Steven R. (Steve) Loranger

Independent Director

76.00K

+6.56%

Mr. Bernard J. Zovighian

Chief Executive Officer, Director

39.57K

+120.44%

Mr. Daniel J. Lippis

Corporate Vice President - Transcatheter Aortic Valve Replacement

21.26K

-17.30%

Mr. Daveen Chopra

Corporate Vice President - Transcatheter Mitral and Tricuspid Therapies

19.21K

+44.48%

Mr. Paul A. Laviolette

Independent Director

11.25K

+45.71%

Dr. David T. Feinberg, M.D.

Independent Director

5.84K

+152.86%

Mr. Nicholas J. (Nick) Valeriani

Independent Chairman of the Board

--

Mr. Kieran T. Gallahue

Independent Director

--

Ver Mais

Nome

Nome/Posição

Posição

Ações detidas

Variação

Mr. Scott B. Ullem

Chief Financial Officer, Corporate Vice President

282.82K

+3.48%

Mr. Larry L. Wood

Corporate Vice President, Group President - Transcatheter Aortic Valve Replacement (TAVR) and Surgical Structural Heart

186.44K

--

Mr. Steven R. (Steve) Loranger

Independent Director

76.00K

+6.56%

Mr. Bernard J. Zovighian

Chief Executive Officer, Director

39.57K

+120.44%

Mr. Daniel J. Lippis

Corporate Vice President - Transcatheter Aortic Valve Replacement

21.26K

-17.30%

Mr. Daveen Chopra

Corporate Vice President - Transcatheter Mitral and Tricuspid Therapies

19.21K

+44.48%

Detalhamento da receita

Moeda: USDAtualizado em: dom, 6 de jul

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

FY2018

FY2017

FY2016

FY2015

Por EmpresaUSD

Nome

Receita

Proporção

Transcatheter Aortic Valve Replacement

1.05B

74.09%

Surgical Heart Valve Therapy

250.90M

17.76%

Transcatheter Mitral and Tricuspid Therapies

115.20M

8.15%

Por RegiãoUSD

Nome

Receita

Proporção

United States

838.90M

59.38%

Europe

341.80M

24.19%

Rest of the world

150.20M

10.63%

Japan

81.80M

5.79%

Por Empresa

Por Região

Por EmpresaUSD

Nome

Receita

Proporção

Transcatheter Aortic Valve Replacement

1.05B

74.09%

Surgical Heart Valve Therapy

250.90M

17.76%

Transcatheter Mitral and Tricuspid Therapies

115.20M

8.15%

Distribuição de ações

Atualizado em: sex, 16 de mai

Investidores

Tipos de investidores

Investidores

Proporção

The Vanguard Group, Inc.

11.75%

BlackRock Institutional Trust Company, N.A.

5.50%

Wellington Management Company, LLP

4.97%

State Street Global Advisors (US)

4.40%

JP Morgan Asset Management

2.79%

Other

70.59%

Investidores

Proporção

The Vanguard Group, Inc.

11.75%

BlackRock Institutional Trust Company, N.A.

5.50%

Wellington Management Company, LLP

4.97%

State Street Global Advisors (US)

4.40%

JP Morgan Asset Management

2.79%

Other

70.59%

Tipos de investidores

Investidores

Proporção

Investment Advisor

43.28%

Investment Advisor/Hedge Fund

31.39%

Hedge Fund

5.44%

Research Firm

2.22%

Pension Fund

2.19%

Bank and Trust

1.92%

Sovereign Wealth Fund

1.53%

Individual Investor

0.92%

Endowment Fund

0.82%

Other

10.30%

Participação acionária institucional

Atualizado em: ter, 1 de jul

Período do relatório

N.º de instituições

Ações detidas

Proporção

Variação

2025Q2

2586

529.26M

90.23%

-21.68M

2025Q1

2628

535.29M

91.24%

-19.91M

2024Q4

2597

531.64M

90.42%

-4.10M

2024Q3

2568

511.38M

84.93%

-20.94M

2024Q2

2559

522.19M

86.68%

-12.58M

2024Q1

2572

518.82M

86.18%

-12.08M

2023Q4

2573

509.93M

84.08%

-27.42M

2023Q3

2530

522.96M

86.03%

-18.75M

2023Q2

2517

523.54M

86.35%

-20.02M

2023Q1

2495

522.98M

86.26%

-32.79M

Ver Mais

Atividade dos acionistas

Nome

Ações detidas

Proporção

Variação

Var. %

Data

The Vanguard Group, Inc.

68.94M

11.75%

+70.46K

+0.10%

Mar 31, 2025

BlackRock Institutional Trust Company, N.A.

32.28M

5.5%

+544.18K

+1.71%

Mar 31, 2025

Wellington Management Company, LLP

29.13M

4.97%

-4.08M

-12.27%

Mar 31, 2025

State Street Global Advisors (US)

25.78M

4.4%

-25.16K

-0.10%

Mar 31, 2025

JP Morgan Asset Management

16.37M

2.79%

+5.61M

+52.12%

Mar 31, 2025

Citadel Advisors LLC

13.38M

2.28%

+3.96M

+42.09%

Mar 31, 2025

Geode Capital Management, L.L.C.

12.68M

2.16%

-970.48K

-7.11%

Mar 31, 2025

Jennison Associates LLC

10.09M

1.72%

+2.58M

+34.31%

Mar 31, 2025

Fisher Investments

10.10M

1.72%

+325.19K

+3.33%

Mar 31, 2025

Walter Scott & Partners Ltd.

9.06M

1.54%

-347.38K

-3.69%

Mar 31, 2025

Ver Mais

ETFs Relacionados

Atualizado em: há 14 horas

Nome

Proporção

iShares U.S. Medical Devices ETF

4.56%

Future Fund Long/Short ETF

3.72%

iShares Health Innovation Active ETF

3.18%

Adaptive Core ETF

3.15%

Global X Aging Population ETF

3.13%

Tema Heart & Health ETF

2.28%

First Trust Indxx Medical Devices ETF

2.08%

SPDR S&P Health Care Equipment ETF

1.89%

Invesco S&P 500 Equal Weight Health Care ETF

1.72%

PGIM Jennison Better Future ETF

1.71%

Ver Mais

iShares U.S. Medical Devices ETF

Proporção4.56%

Future Fund Long/Short ETF

Proporção3.72%

iShares Health Innovation Active ETF

Proporção3.18%

Adaptive Core ETF

Proporção3.15%

Global X Aging Population ETF

Proporção3.13%

Tema Heart & Health ETF

Proporção2.28%

First Trust Indxx Medical Devices ETF

Proporção2.08%

SPDR S&P Health Care Equipment ETF

Proporção1.89%

Invesco S&P 500 Equal Weight Health Care ETF

Proporção1.72%

PGIM Jennison Better Future ETF

Proporção1.71%

Dividendo

Um total de 0.00 USD foi distribuído em dividendos nos últimos 5 anos.

Data

Dividendo

Data de registro

Data de pagamento

Data ex-dividendo

Sem dados

Desdobramento de ações

Data

Tipo

Proporção

May 07, 2020

Split

1>3

Data

Tipo

Proporção

May 07, 2020

Split

1>3

Edwards Lifesciences Corp

79.330USD

Edwards Lifesciences Corp

79.330

Visão Geral

Empresa

Serviços Financeiros